Latest Content

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her session on the hormonal and aesthetic considerations ODs should make when treating these patients.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for Vizz in Australia and New Zealand.

The meeting featured advances in contact lens technology, evolving approaches to keratoconus management, and new insights into dry eye disease treatment.

Ping Moore, OD, outlines modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Jade Coats, OD, FAAO, details what has changed in dry eye treatment in the last decade, and how to optimize the ocular surface through the power of comanagement.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

Justin Schweitzer, OD, FAAO, details how to distinguish secondary glaucomas from primary glaucomas in a recent presentation.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.

Host Hamza Shah, OD, MS, FAAO, is joined by Brianna Rhue, OD, FAAO, to discuss eye care terminology, inspired by Zhang et al's paper, "Myopia Progression Management: Current Trends and Future Directions."

An overview of the diagnosis and evidence-based management of one of the most common causes of visual acuity reduction following intraocular surgery.

In a preference study, Karl Csaky, MD, PhD and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.